Cancer Stem Cell News Volume 10.32 | Aug 18 2021

    0
    4







    2021-07-18 | CSCN 10.32


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.32 – 18 August, 2021
    TOP STORY

    The Requirement for Pyruvate Dehydrogenase in Leukemogenesis Depends on Cell Lineage

    Investigators compared glucose metabolism in hematopoiesis and leukemia. Thymus T cell progenitors were glucose avid and oxidized more glucose in the tricarboxylic acid cycle through pyruvate dehydrogenase as compared with other hematopoietic cells.
    [Cell Metabolism]

    AbstractGraphical Abstract
    Find the Right Antibodies for Your Stem Cell Research. Learn More
    PUBLICATIONSRanked by the impact factor of the journal

    CAFs Shape Myeloid-Derived Suppressor Cells to Promote Stemness of Intrahepatic Cholangiocarcinoma via 5-Lipoxygenase

    Researchers investigated whether and how cancer-associated fibroblasts (CAFs) regulates myeloid-derived suppressor cells function to enhance cancer stemness, the driving force of the cancer aggressiveness and chemotherapy refractoriness, in highly desmoplastic intrahepatic cholangiocarcinoma.
    [Hepatology]

    Abstract

    Adipose Stem Cell Niche Reprograms the Colorectal Cancer Stem Cell Metastatic Machinery

    Visceral adipose-derived factors promoted vasculogenesis and the onset of metastatic dissemination by activation of STAT3, which inhibited miR-200a and enhanced ZEB2 expression, effectively reprogramming colorectal cancer cells into a highly metastatic phenotype.
    [Nature Communications]

    Full Article

    BAZ2A-Mediated Repression via H3K14ac-Marked Enhancers Promotes Prostate Cancer Stem Cells

    Scientists showed that BAZ2A was required for prostate cancer (PCa) cells with a cancer stem-like state. BAZ2A genomic occupancy in PCa cells coincided with H3K14ac-enriched chromatin regions.
    [EMBO Reports]

    Full ArticleGraphical Abstract

    GRIK2 Is a Target for Bladder Cancer Stem-Like Cell-Targeting Immunotherapy

    Investigators established a novel bladder CSC/cancer-initiating cells (CICs) model from a bladder cancer cell line using an ALDEFLUOR assay. CSCs/CICs were isolated as aldehyde dehydrogenase (ALDH)-high cells and several ALDHhigh clone cells were established.
    [Cancer Immunology Immunotherapy]

    Abstract

    Thrombopoietin-Based CAR-T Cells Demonstrate In Vitro and In Vivo Cytotoxicity to MPL Positive Acute Myelogenous Leukemia and Hematopoietic Stem Cells

    CAR T cells were designed using a ligand binding domain instead of a single chain variable fragments to target stem-like leukemia cells. Thrombopoietin, the natural ligand to the myeloproliferative leukemia protein (MPL) receptor, was used as the antigen binding domain to engage MPL expressed on hematopoeitic stem cells and erythropoietic and megakaryocytic acute myeloid leukemias.
    [Gene Therapy]

    Full Article

    Prognostic Significance of TIM-3 Expression Pattern at Diagnosis in Patients with t(8; 21) Acute Myeloid Leukemia

    The authors investigated the prognostic significance of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) in t(8;21) acute myeloid leukemia (AML). A total of 47 t(8;21) AML patients were tested for TIM-3 expression by multi-parameter flow cytometry at diagnosis.
    [Leukemia & Lymphoma]

    Abstract

    Preferential Interaction of Platelets with Prostate Cancer Cells with Stem Cell Markers

    Scientists characterized the mechanisms behind prostate CSC-platelet interaction. Fluorescence Activated Cell Sorting was utilized to separate DU145 and PC3 prostate cancer cells into CD133+/CD44+, CD133+/CD44, CD44+/CD133, and CD133/CD44 subpopulations and to measure their CXCR4 surface expression.
    [Thrombosis Research]

    Abstract

    Phenotypic Changes on Central Nervous System (CNS) Tumor Cell Lines Cultured In Vitro 2D and 3D Models and Treated with Cisplatin

    Researchers evaluated platinum-based response in brain tumor U-87 MG, LN-18, and KELLY cell lines cultured in monolayer and neurosphere models as well as mRNA expression of heat shock proteins and DNA repair gene ERCC1.
    [Acta Histochemica]

    AbstractGraphical Abstract

    Targeting PUS7 Suppresses tRNA Pseudouridylation and Glioblastoma Tumorigenesis

    Investigators identified chemical inhibitors for seudouridine synthase 7 (PUS7) and showed that these compounds prevented PUS7-mediated pseudouridine modification, suppressed tumorigenesis and extended the life span of tumor-bearing mice.
    [Nature Cancer]

    Abstract

    Banner Ad Cross Reference Banner Ad Cross Reference 100% 10 E17 Visit the Hematopoiesis Resource Center for videos, tips, and protocols to help with your research questions. Screen reader support enabled. Visit the Hematopoiesis Resource Center for videos, tips, and protocols to help with your research questions. Turn on screen reader support
    REVIEWS

    Cancer Biology Deciphered by Single-Cell Transcriptomic Sequencing

    To study cancer cells, single-cell RNA srequencing has provided novel insights into the CSC-like model, treatment resistance, and cancer metastasis.
    [Protein & Cell]

    Full Article

    Cancer Stem Cell-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy: Challenges and Prospects

    The authors review the CSC markers that have been previously targeted with CAR-T cells, as well as the CSC markers that may be used as possible targets for CAR-T cell therapy in the future.
    [Acta Pharmaceutica Sinica B]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Biosight Announces Initiation of Investigator Sponsored Phase II Clinical Trial of Aspacytarabine for Relapsed/Refractory AML and MDS with the Groupe Francophone Des Myélodysplasies

    Biosight Ltd. announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome or acute myeloid leukemia.
    [Biosight Ltd. (Globe Newswire)]

    Press Release

    Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

    Carrick Therapeutics announced that the US FDA has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2 advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic triple-negative breast cancer.
    [Carrick Therapeutics]

    Press Release
    FEATURED EVENT

    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    October 7 – 11, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Faculty Position – Cancer Biology and Signal Transduction

    Purdue University – West Lafayette, Indiana, United States

    Principal Medical Scientist – Oncology

    Gilead Sciences, Inc. – Foster City, California, United States

    Postdoctoral Fellow – Obesity, Diabetes and Cancer

    City of Hope – Duarte, California, United States

    Research Scientist – Cancer Immunotherapy Drug Discovery

    Incyte – Wilmington, Delaware, United States

    Postdoctoral Fellow – Glioma Stem Cells

    MD Anderson Cancer Center – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter